Literature DB >> 3875807

Intellectual changes in patients with MPTP-induced parkinsonism.

Y Stern, J W Langston.   

Abstract

We studied six patients with MPTP-induced parkinsonism to assess intellectual function, attention, reaction time, and depression. Eight controls with a similar history of drug abuse also participated. General intellectual function, construction, category naming, and frontal lobe function were worse in the patients; other aspects of performance were comparable. All affected women but none of the men were depressed, usually before onset of parkinsonism. The pattern of intellectual deficit in the MPTP patients was similar to that of idiopathic Parkinson's disease. Since MPTP-induced parkinsonism probably represents a purely dopaminergic deficiency, these findings suggest that changes in the dopamine system are responsible for at least some of the intellectual changes of idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875807     DOI: 10.1212/wnl.35.10.1506

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

Authors:  Anissa Abi-Dargham
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 2.  Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

Authors:  B Dubois; B Pillon; Y Agid
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

Review 3.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

Review 4.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

5.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

Authors:  Chadwick W Christine; J William Langston; Robert S Turner; Philip A Starr
Journal:  J Neurosurg       Date:  2009-02       Impact factor: 5.115

Review 7.  'Designer drugs'. A problem in clinical toxicology.

Authors:  J F Buchanan; C R Brown
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec

8.  Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.

Authors:  J R Taylor; J D Elsworth; R H Roth; J R Sladek; T J Collier; D E Redmond
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

Review 9.  Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.

Authors:  Caroline H Williams-Gray; Thomas Foltynie; Simon J G Lewis; Roger A Barker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.

Authors:  Anissa Abi-Dargham; Jonathan A Javitch; Mark Slifstein; Alan Anticevic; Monica E Calkins; Youngsun T Cho; Clara Fonteneau; Roberto Gil; Ragy Girgis; Raquel E Gur; Ruben C Gur; Jack Grinband; Joshua Kantrowitz; Christian Kohler; John Krystal; John Murray; Mohini Ranganathan; Nicole Santamauro; Jared Van Snellenberg; Zailyn Tamayo; Daniel Wolf; David Gray; Jeffrey Lieberman
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.